Family Medicine
Review: chronic pelvic pain in women.
17 Jun, 2021 | 09:36h | UTCChronic Pelvic Pain in Women: A Review – JAMA (free for a limited period)
Audio clinical review: Diagnosis and Clinical Care of Women With Chronic Pelvic Pain
Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.
16 Jun, 2021 | 08:31h | UTCAlmost 25% of COVID-19 Patients Develop Long-Lasting Symptoms, According to a New Report – TIME
Original report: A Detailed Study of Patients with Long-Haul COVID – FAIR Health
Commentary on Twitter (thread – click for more)
📍1 in 4–almost a quarter of people infected develop at least one lingering health problem after 30 days with #COVID19. The most common included pain, breathing trouble, high cholesterol, malaise and/or fatigue and high blood pressure. 🧵 https://t.co/G4uPtnq86A
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
Cardio-pulmonary sequelae in recovered COVID-19 patients: considerations for primary care.
16 Jun, 2021 | 08:29h | UTC
M-A: The incubation period distribution of coronavirus disease 2019 – “the mean incubation period of COVID-19 was likely to fall between 5.2 and 7.2 days, and the 95th percentile would be between 11 and 14.6 days”.
16 Jun, 2021 | 08:27h | UTC
A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.
16 Jun, 2021 | 08:26h | UTCA long-term perspective on immunity to COVID – Nature
France recommends single dose of vaccine if previous Covid infection detected.
16 Jun, 2021 | 08:24h | UTCFrance recommends single dose of vaccine if previous Covid infection detected – Rfi
Related: [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Review: General health checks in adult primary care.
16 Jun, 2021 | 08:13h | UTCGeneral Health Checks in Adult Primary Care: A Review – JAMA (free for a limited period)
Editorial: The Routine General Medical Checkup: Valuable Practice or Unnecessary Ritual? – JAMA
Podcast: General Health Checks in Adult Primary Care
RCT: A brief advice + nicotine replacement therapy sampling + active referral nearly doubled the odds of validated quitting among expectant fathers who smoked.
16 Jun, 2021 | 08:15h | UTCBrief Advice, Nicotine Replacement Therapy Sampling, and Active Referral for Expectant Fathers Who Smoke Cigarettes: A Randomized Clinical Trial – JAMA Internal Medicine (free for a limited period)
WHO official: Delta variant ‘poised to take hold’ in Europe.
15 Jun, 2021 | 09:06h | UTCWHO official: Delta variant ‘poised to take hold’ in Europe – The Hill
[Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant.
15 Jun, 2021 | 09:09h | UTCNews Release: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Commentary on Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— UK Health Security Agency (@UKHSA) June 14, 2021
(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.
15 Jun, 2021 | 09:12h | UTCCommentaries: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases AND Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT AND Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science AND Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP AND What the Novavax vaccine means for the global fight against Covid-19 – Vox
Commentary on Twitter (thread – click for more)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
SARS-CoV-2 Delta variant in Scotland: demographics, risk of hospital admission, and vaccine effectiveness – “Risk of COVID-19 hospital admission was approximately doubled in those with the Delta VOC when compared to the Alpha VOC”.
15 Jun, 2021 | 09:10h | UTCCommentaries: Delta may raise hospitalisation but vaccine still protects – UK Research and Innovation AND Expert reaction to Lancet research letter analysing data from Scotland on the Delta variant, looking at demographics, risk of hospital admission and vaccine effectiveness – Science Media Centre
Commentary on Twitter (thread – click for more)
Just published @TheLancet
The #DeltaVariant experience in Scotlandhttps://t.co/IfjDJnCAMC
1. #VaccinesWork ("AZ appeared less effective than Pfizer")
2. Younger, unvaccinated got the delta infections
3. Doubling of hospital admissions compared with alpha (B.1.1.7) variant pic.twitter.com/cP8clu57Rd— Eric Topol (@EricTopol) June 14, 2021
Delta variant producing more severe illness, doctors in China say.
15 Jun, 2021 | 09:02h | UTCIn China’s latest outbreak, doctors say the infected get sicker, faster. – The New York Times (a few articles per month are free)
Delta variant causes more than 90% of new Covid cases in UK.
15 Jun, 2021 | 09:04h | UTCDelta variant causes more than 90% of new Covid cases in UK – The Guardian
Commentary on Twitter (thread – click for more)
⚠️90-96% of all #COVID19 in 🇬🇧 caused by #DeltaVariant.🧵
📍32% of all Delta cases visiting the hospital emergency room are at least 1 dose vaccinated
📍33% who are then hospitalized vaccinated
📍45% of all deaths got at least 1 shot—➡️ 29% got 2 shots.https://t.co/RViq5NiioQ pic.twitter.com/v2OYV2GM09
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
A new coronavirus variant (Delta) is on the rise. Here’s why experts are concerned.
15 Jun, 2021 | 09:03h | UTCA new coronavirus variant is on the rise. Here’s why experts are concerned – CNN
M-A: Ibuprofen and other NSAIDs superior to codeine for managing outpatient postoperative pain.
15 Jun, 2021 | 08:55h | UTCOriginal Article: Managing postoperative pain in adult outpatients: a systematic review and meta-analysis comparing codeine with NSAIDs – Canadian Medical Association Journal
Parental education and inequalities in child mortality: a global systematic review and meta-analysis.
15 Jun, 2021 | 08:52h | UTCCommentaries: Children of well-educated people have higher survival rates – Norwegian University of Science and Technology AND Parental education’s role in child survival – The Lancet
Commentary on Twitter (thread – click for more)
NEW study suggests lower parental education is a risk factor for child mortality, even after controlling for other markers of family socioeconomic status.
Thus, universal quality education could help ⬇️ neonatal & child mortality (#SDG target 3.2). Read https://t.co/1saJ9KwUyC. pic.twitter.com/5pctnQft4M
— The Lancet (@TheLancet) June 12, 2021
M-A: Among patients with kidney failure treated with dialysis, mineralocorticoid receptor antagonists reduce cardiovascular and all-cause mortality without increasing the risk of hyperkalemia.
15 Jun, 2021 | 08:53h | UTCEfficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
Patients with kidney failure have a high risk of cardiovascular diseases. This meta-analysis suggests that mineralocorticoid receptor antagonists might improve clinical outcomes of patients with kidney failure without a major increase in hyperkalemia risk https://t.co/o3aO3KK2S6 pic.twitter.com/5xuCgs6FbQ
— CJASN (@CJASN) June 14, 2021
Podcast | Dominate stable angina with the CardioNerds.
15 Jun, 2021 | 08:51h | UTC#279 Dominate Stable Angina with the CardioNerds – The Curbsiders
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – “no evidence of a difference between the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines”.
14 Jun, 2021 | 08:52h | UTCImpact of vaccination on new SARS-CoV-2 infections in the United Kingdom – Nature Medicine
Commentaries on Twitter
The ChAdOx1 nCoV-19 and BNT162b2 #COVID19 #vaccines reduce incidence of new #SARSCoV2 infections by up to 65% with a single dose and up to 80% after two doses in the United Kingdom @kb_pouwels @ONS @Oxford_NDPH @UniofOxford https://t.co/K1f68MMYyO
— Nature Medicine (@NatureMedicine) June 9, 2021
First-dose vaccination with the Oxford–AstraZeneca or Pfizer–BioNTech vaccine against SARS-CoV-2 reduced the incidence of new infections in the UK by 61% and 66%, respectively, according to a study in @NatureMedicine. https://t.co/2TUFE1DeII pic.twitter.com/KuMtc1cD7l
— Nature Portfolio (@NaturePortfolio) June 9, 2021
Viewpoint | Active surveillance as a management option for low-risk basal cell carcinoma.
15 Jun, 2021 | 08:49h | UTC
Lab study shows sera from persons fully vaccinated with the Pfizer–BioNTech vaccine can effectively neutralize B.1.617 (Delta) and other SARS-CoV-2 variants.
14 Jun, 2021 | 08:53h | UTCBNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants – Nature
Commentary on Twitter
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 and B.1.525. https://t.co/7lXCVe7sPY
— Carlos del Rio (@CarlosdelRio7) June 12, 2021
Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.
14 Jun, 2021 | 08:48h | UTCCommentary: MIS-C Incidence 316 Persons Per 1 Million SARS-CoV-2 Infections – HealthDay
Commentary on Twitter
About 1 in every 3,000 children who got COVID ended up with MIS-C. MIS-C incidence among Black persons and Hispanic or Latino persons was approximately 9x higher, and incidence among Asian or Pacific Islander persons was approximately 3x higher https://t.co/JTEsvgvFcz
— Daniel Griffin MD PhD (@DanielGriffinMD) June 12, 2021
Children with symptomatic SARS-CoV-2 infection have similar viral loads and may be as contagious as symptomatic adults.
14 Jun, 2021 | 08:49h | UTCEditorial: Implications of SARS-CoV-2 Viral Load in Children: Getting Back to School and Normal
Commentary on Twitter (thread – click for more)
In a new study in @JAMAPediatrics, we compared symptoms and viral load in children and adults with SARS-CoV-2. Those with symptoms had higher virus loads than those without. Importantly, within these groups – viral load was the same in children and adults. https://t.co/UgaFzvMNlg pic.twitter.com/cjpt2yqQ3R
— Helen Chu (@HelenChuMD) June 11, 2021
Video | Evaluation and care of patients with persistent symptoms following acute SARS-CoV-2 infection.
14 Jun, 2021 | 08:45h | UTC